drugset / Trial / NCT05254899
Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL
Phase 2
Unknown
54 enrolled
Chinese Academy of Medical Sciences
Peking University Cancer Hospital & Institute · collabThe Affiliated Hospital Of Guizhou Medical University · collabThe First Hospital of Jilin University · collab
NaSingle-groupOpen-labelTreatment
Summary
The current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of inductive Anti-PD-1+P-GEMOX treatment followed by radiotherapy and concurrent Anti-PD-1 antibody in early-stage high-risk extranodal NK/T cell lymphoma, nasal type
Timeline
- Start
- 2021-10-01
- Primary completion
- 2022-09-30
- Completion
- 2024-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Background | Oxaliplatin | Small molecule | 1000 mg/m2 | Intravenous |
| Background | Pegaspargase | Protein / enzyme biologic | 3000 unknown | Intramuscular |
| Background | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |